Literature DB >> 22907373

Fc engineering: serum half-life modulation through FcRn binding.

Tove Olafsen1.   

Abstract

Controlling the half-life of pharmaceuticals through Fc engineering is a desirable approach to achieve optimal exposure and targeting. The long serum residence time of gamma immunoglobulins is attributed to the Fc binding to the neonatal Fc receptor (FcRn). The residues in the Fc region that interact with FcRn have been mapped and individual mutations of these residues have demonstrated reduced affinity to FcRn and faster blood clearance. Here, we describe site-specific mutagenesis of Fc residues in a scFv-Fc fusion protein, as well as the mammalian production, purification, characterization, and the in vivo pharmacokinetics of these antibody fragments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907373     DOI: 10.1007/978-1-61779-974-7_31

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Evading pre-existing anti-hinge antibody binding by hinge engineering.

Authors:  Hok Seon Kim; Ingrid Kim; Linda Zheng; Jean-Michel Vernes; Y Gloria Meng; Christoph Spiess
Journal:  MAbs       Date:  2016-08-09       Impact factor: 5.857

Review 2.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

Review 3.  Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.

Authors:  James R Kintzing; Maria V Filsinger Interrante; Jennifer R Cochran
Journal:  Trends Pharmacol Sci       Date:  2016-11-09       Impact factor: 14.819

Review 4.  Progress toward inducing immunologic tolerance to factor VIII.

Authors:  David W Scott; Kathleen P Pratt; Carol H Miao
Journal:  Blood       Date:  2013-03-15       Impact factor: 22.113

5.  Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.

Authors:  Joshua W Wang; Wai Hong Wu; Tsui-Chin Huang; Margaret Wong; Kihyuck Kwak; Keiko Ozato; Chien-Fu Hung; Richard B S Roden
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

6.  Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments.

Authors:  Diana Gil; Adam G Schrum
Journal:  Adv Biosci Biotechnol       Date:  2013-04

Review 7.  Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.

Authors:  Liming Liu
Journal:  Protein Cell       Date:  2017-04-19       Impact factor: 14.870

Review 8.  Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.

Authors:  Bushra Husain; Diego Ellerman
Journal:  BioDrugs       Date:  2018-10       Impact factor: 5.807

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.